References
- Hauser W, Hesdorffer D. Facts About Epilepsy. The Epilepsy Foundation, MD USA (1994).
- National Institute for Health and Clinical Excellence. Newer Drugs for Epilepsy in Adults (Technology Appraisal 76). NICE, London, UK (2004).
- Hauser W. Epilepsy: Frequency, Causes, and Consequences. Demos Press, NY, USA (1990).
- Hitiris N, Mohanraj R, Norrie J, Brodie MJ. Mortality in epilepsy. Epilepsy Behav.10(3), 363–376 (2007).
- Pugliatti M, Beghi E, Forsgren L, Ekman M, Sobocki P. Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia48(12), 2224–2233 (2007).
- Brodie MJ, Dichter MA. Established antiepileptic drugs. Seizure6(3), 159–174 (1997).
- Perucca E, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurol. Scand. Suppl.181, 30–35 (2005).
- French JA. Refractory epilepsy: one size does not fit all. Epilepsy Curr.6(6), 177–180 (2006).
- Brodie MJ. Modern approaches to epilepsy management. Eur. Neurol. Dis.31–32 (2006).
- Brodie MJ. Epilepsy: randomised trials and genetic tribulations. Lancet Neurol.7(1), 7–8 (2008).
- Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur. J. Neurol.13(3), 277–282 (2006).
- Leppik I, Morrell M, Godfroid P, Arrigo C. Seizure-free days observed in randomized placebo-controlled add-on trials with levetiracetam in partial epilepsy. Epilepsia44(10), 1350–1352 (2003).
- Wilby J, Kainth A, Hawkins N et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol. Assess.9(15), 1–157, III–IV (2005).
- Drummond M, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes (3rd Edition). Oxford University Press, Oxford, UK (2005).
- Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ313(7052), 275–283 (1996).
- Beghi E, Atzeni L, Garattini L. Economic analysis of newer antiepileptic drugs. CNS Drugs22(10), 861–875 (2008).
- Spackman D, Yeates A, Rentz A, Hutton J. The cost effectiveness of zonisamide as adjunctive therapy in adult partial seizure epilepsy. J. Med. Econ.10, 455–473 (2007).
- Vera-Llonch M, Brandenburg NA, Oster G. Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy. Epilepsia49(3), 431–437 (2008).
- SP667/Phase 2/multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to investigate the efficacy and safety of lacosamide (200, 400 and 600 mg/day). Company data on file: UCB Pharma, Brussels, Belgium (2009).
- SP754/Phase 3/multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to investigate the efficacy and safety of lacosamide (400 and 600 mg/day). Company data on file: UCB Pharma, Brussels, Belgium (2009).
- SP755/Phase 3/multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to investigate the efficacy and safety of lacosamide (200 and 400 mg/day). Company data on file: UCB Pharma, Brussels, Belgium (2009).
Website
- European Medicines Agency. Assessment report for Vimpat (lacosamide) (2008) www.ema.europa.eu/humandocs/PDFs/EPAR/vimpat/H-863-en6.pdf